Christopher Raymond
Stock Analyst at Raymond James
(3.32)
# 2,390
Out of 4,463 analysts
880
Total ratings
44.8%
Success rate
2.4%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLYM Climb Bio | Maintained: Buy | n/a | $13.29 | - | 3 | Jun 24, 2026 | |
| BHVN Biohaven | Maintained: Buy | n/a | $15.76 | - | 22 | Jun 24, 2026 | |
| AKTS Aktis Oncology | Initiated Coverage: Buy | $40 | $30.89 | +29.49% | 1 | Jun 16, 2026 | |
| NUVL Nuvalent | Downgraded: Hold | n/a | $123.60 | - | 14 | Jun 9, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Buy | n/a | $57.82 | - | 86 | May 22, 2026 | |
| ALMS Alumis | Maintained: Buy | $46 | $26.64 | +72.67% | 2 | Mar 27, 2026 | |
| TYRA Tyra Biosciences | Maintained: Buy | $35 → $55 | $29.41 | +87.01% | 7 | Feb 23, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintained: Buy | $723 → $870 | $624.72 | +39.26% | 114 | Jan 30, 2026 | |
| COGT Cogent Biosciences | Maintained: Buy | $60 | $38.48 | +55.93% | 20 | Jan 26, 2026 | |
| LXEO Lexeo Therapeutics | Maintained: Buy | $25 | $4.45 | +461.80% | 2 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 → $19 | $5.16 | +268.22% | 41 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $47 | $5.62 | +736.30% | 1 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 | $6.65 | +95.49% | 6 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $142 → $123 | $95.03 | +29.43% | 5 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $26 → $29 | $12.80 | +126.56% | 11 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $361.33 | - | 78 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $23 | $4.53 | +407.73% | 14 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $533 → $401 | $498.01 | -19.48% | 26 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 | $5.34 | n/a | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $140 | $32.38 | n/a | 58 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $20 → $4 | $12.60 | n/a | 6 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 | $132.56 | n/a | 5 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $220 → $227 | $251.06 | n/a | 84 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $75 | $9.55 | n/a | 21 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $307 → $315 | $209.74 | n/a | 91 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $20 | $9.65 | n/a | 19 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $56 | $37.08 | n/a | 11 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 | $0.0061 | n/a | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $21 → $8 | $2.06 | n/a | 24 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $58 | $79.19 | n/a | 1 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $1.21 | n/a | 22 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $600 | $909.50 | n/a | 1 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $22 | $56.34 | n/a | 1 | Jul 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $2.39 | n/a | 1 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $28 | $1.04 | n/a | 5 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $28 | $35.56 | n/a | 1 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 | $6.55 | n/a | 6 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $75 → $30 | $10.20 | n/a | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7 → $6 | $1.19 | n/a | 20 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $38.29 | n/a | 12 | Apr 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $5.19 | n/a | 4 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $33.44 | n/a | 1 | Apr 18, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.04 | n/a | 6 | Aug 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $42 → $101 | - | n/a | 2 | Mar 31, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.0013 | n/a | 6 | Mar 19, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $3 → $6 | $3.00 | n/a | 3 | Feb 29, 2012 |
Climb Bio
Jun 24, 2026
Maintained: Buy
Price Target: n/a
Current: $13.29
Upside: -
Biohaven
Jun 24, 2026
Maintained: Buy
Price Target: n/a
Current: $15.76
Upside: -
Aktis Oncology
Jun 16, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $30.89
Upside: +29.49%
Nuvalent
Jun 9, 2026
Downgraded: Hold
Price Target: n/a
Current: $123.60
Upside: -
BioMarin Pharmaceutical
May 22, 2026
Maintained: Buy
Price Target: n/a
Current: $57.82
Upside: -
Alumis
Mar 27, 2026
Maintained: Buy
Price Target: $46
Current: $26.64
Upside: +72.67%
Tyra Biosciences
Feb 23, 2026
Maintained: Buy
Price Target: $35 → $55
Current: $29.41
Upside: +87.01%
Regeneron Pharmaceuticals
Jan 30, 2026
Maintained: Buy
Price Target: $723 → $870
Current: $624.72
Upside: +39.26%
Cogent Biosciences
Jan 26, 2026
Maintained: Buy
Price Target: $60
Current: $38.48
Upside: +55.93%
Lexeo Therapeutics
Jan 13, 2026
Maintained: Buy
Price Target: $25
Current: $4.45
Upside: +461.80%
Jan 8, 2026
Maintained: Buy
Price Target: $14 → $19
Current: $5.16
Upside: +268.22%
Dec 2, 2025
Initiated Coverage: Buy
Price Target: $47
Current: $5.62
Upside: +736.30%
Nov 25, 2025
Maintained: Buy
Price Target: $13
Current: $6.65
Upside: +95.49%
Nov 14, 2025
Maintained: Buy
Price Target: $142 → $123
Current: $95.03
Upside: +29.43%
Oct 20, 2025
Initiated Coverage: Buy
Price Target: $26 → $29
Current: $12.80
Upside: +126.56%
Oct 10, 2025
Maintained: Hold
Price Target: n/a
Current: $361.33
Upside: -
Sep 16, 2025
Maintained: Buy
Price Target: $23
Current: $4.53
Upside: +407.73%
Sep 2, 2025
Initiated Coverage: Hold
Price Target: $533 → $401
Current: $498.01
Upside: -19.48%
Feb 18, 2025
Maintained: Buy
Price Target: $13
Current: $5.34
Upside: n/a
Feb 14, 2025
Maintained: Buy
Price Target: $140
Current: $32.38
Upside: n/a
Feb 11, 2025
Downgraded: Hold
Price Target: $20 → $4
Current: $12.60
Upside: n/a
Feb 10, 2025
Maintained: Buy
Price Target: $42
Current: $132.56
Upside: n/a
Jan 27, 2025
Rated: Buy
Price Target: $220 → $227
Current: $251.06
Upside: n/a
Jan 27, 2025
Rated: Buy
Price Target: $75
Current: $9.55
Upside: n/a
Oct 30, 2024
Maintained: Buy
Price Target: $307 → $315
Current: $209.74
Upside: n/a
Oct 23, 2024
Rated: Buy
Price Target: $20
Current: $9.65
Upside: n/a
Oct 23, 2024
Rated: Buy
Price Target: $56
Current: $37.08
Upside: n/a
Sep 16, 2024
Rated: Buy
Price Target: $10
Current: $0.0061
Upside: n/a
Aug 9, 2024
Rated: Buy
Price Target: $21 → $8
Current: $2.06
Upside: n/a
Oct 25, 2023
Maintained: Buy
Price Target: $58
Current: $79.19
Upside: n/a
Oct 25, 2023
Maintained: Buy
Price Target: $4
Current: $1.21
Upside: n/a
Oct 25, 2023
Maintained: Buy
Price Target: $600
Current: $909.50
Upside: n/a
Jul 24, 2023
Rated: Hold
Price Target: $22
Current: $56.34
Upside: n/a
Apr 25, 2023
Maintained: Buy
Price Target: $14
Current: $2.39
Upside: n/a
Nov 22, 2022
Maintained: Hold
Price Target: $28
Current: $1.04
Upside: n/a
Jul 25, 2022
Initiated Coverage: Buy
Price Target: $28
Current: $35.56
Upside: n/a
May 23, 2022
Maintained: Buy
Price Target: $3
Current: $6.55
Upside: n/a
May 18, 2022
Maintained: Hold
Price Target: $75 → $30
Current: $10.20
Upside: n/a
May 11, 2021
Maintained: Hold
Price Target: $7 → $6
Current: $1.19
Upside: n/a
Apr 13, 2021
Maintained: Buy
Price Target: $8
Current: $38.29
Upside: n/a
Mar 27, 2020
Maintained: Buy
Price Target: n/a
Current: $5.19
Upside: n/a
Apr 18, 2019
Maintained: Hold
Price Target: n/a
Current: $33.44
Upside: n/a
Aug 7, 2017
Rated: Hold
Price Target: n/a
Current: $4.04
Upside: n/a
Mar 31, 2015
Downgraded: Hold
Price Target: $42 → $101
Current: -
Upside: n/a
Mar 19, 2013
Maintained: Hold
Price Target: n/a
Current: $0.0013
Upside: n/a
Feb 29, 2012
Upgraded: Buy
Price Target: $3 → $6
Current: $3.00
Upside: n/a